Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Muta Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Login
aviator crash game
Email Address
Password
Remember Me
Log In
Create an Account
Reset your password
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Muta Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
October 28, 2024: Pneumococcal Vaccination
A 62-year-old man had a 23-valent pneumococcal polysaccharide vaccine (PPSV23) as his first pneumococcal vaccine at age 50 years. He had a 13-valent pneumococcal conjugate vaccine (PCV13) vaccine at age 55 years and a PPSV23 vaccine at age 60 years. What vaccine should he receive at age 65 years?
A. PPSV23 and a final 20-valent or 21-valent pneumococcal conjugate vaccine (PCV20 or PCV21) 5 years later
B. PCV13 as his final vaccine
C. 15-valent pneumococcal conjugate vaccine (PCV15) and a final PPSV23 5 years later
D. PCV20 or PCV21 as his final vaccine
View On-Demand Webinar
View Archived Questions
Leave Feedback
Subscribe
CLOSE